Overview

Renaparin® in Kidney Transplantation

Status:
Completed
Trial end date:
2020-04-21
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of Renaparin in adult patients receiving a deceased donor kidney treated ex-vivo with Renaparin prior to transplantation. Half the patient group will receive a kidney treated with Renaparin, while the other half of the patient group will receive a kidney treated with placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Corline Biomedical AB